Market Size of Global Clinical Oncology NGS Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 16.90 % |
Fastest Growing Market | North America |
Largest Market | Asia-Pacific |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Clinical Oncology NGS Market Analysis
The Clinical Oncology NGS Market is expected to grow at the registered CAGR of 16.9% during the forecast period, 2022-2027.
COVID-19 significantly impacts the clinical oncology NGS market. The guidelines issued by the government of different countries for availing the treatment of cancer during the pandemic are also driving the market's growth. For instance, the Ministry of Health and Family Welfare (MOHFW), the Government of India, released guidelines in March 2020, reporting that Cancer treatment is considered a high priority essential non-COVID-19 healthcare facility. However, a National Cancer Institute article in March 2021 reported that cancer screening decreased during COVID-19. Additionally, The NGS diagnostic technology has the potential advantage of determining the genetic sequence of a virus and helping scientists understand the mutations. Throughout the COVID-19 pandemic, government authorities worldwide constantly work with the private sector to bring NGS technology as a potential diagnostic tool into the market. For instance, in June 2020, the United States Food and Drug Administration (USFDA) issued an emergency use authorization (EUA) to Illumina Inc. for the first COVID-19 diagnostic test utilizing next-generation sequence technology.
The global clinical oncology next-generation sequencing market is driven by factors such as the growing popularity of personalized medicine in clinical oncology, decreasing in cost of genetic medicine, the rising prevalence of cancer, the growing need for early cancer diagnosis and treatment, and the continued advancements in cancer research.
Personalized medicine involves the use of an individual's genetic profile (genome) in the prevention, diagnosis, and treatment of diseases and has the potential to offer the best response and highest safety to ensure better result outcomes. The market is expected to grow with advancements in precision therapies and diagnostics, coupled with breakthrough innovations, such as Next Generation Sequencing (NGS). Moreover, the rise in clinical applications of next-generation sequencing in precision oncology has fueled key companies' efforts to develop novel platforms for genomic assays. For instance, in February 2021, Gabriel Precision Oncology Ltd. and Congenica collaborated to develop an automatic clinical oncology interpretation software platform. Such developments are expected to boost the growth of the market.
Increasing cancer prevalence is driving the global clinical oncology next generation sequencing market. For Instance, According to Global Cancer Observatory (GLOBOCAN 2020) report, there were an estimated 19,292,789 new cancer cases and 9,958,133 deaths globally due to cancers. The breast cancer accounting for 2,261,419 new cancer cases in 2020, followed by lung (2,206,771), colorectum (1,931,590), prostate (1,414,259) and stomach (1,089,103) new cancer cases in 2020 worldwide.
Another factor boosting the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing techniques provide a high percentage of reads and low cost per reading. Leading players are introducing low-cost sequencing techniques. According to the study titled "Innovation at Illumina: The road to the USD 600 human genome," published in the Nature Portfolio in February 2021, A human genome can now be sequenced for USD 600 (down from USD 10,000 previously), with some speculating that a USD 100 genome is not far behind. Human genome sequencing has become more affordable, allowing researchers and clinicians to apply their knowledge to studying diseases and phenotypes.
Thus, all the aforementioned factors are expected to boost the market over the forecast period. However, lack of computational efficiency for data management and inadequate reimbursement policy are the major restraining factors for the market studied.
Clinical Oncology NGS Industry Segmentation
As per the scope of the report, NGS has been adopted in clinical oncology to advance the personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide a molecular rationale for appropriate targeted therapy. Technology segments the Clinical Oncology NGS Market (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing Centrifuges), Workflow (Pre-Sequencing, Sequencing, Data Analysis), Application (Screening, Companion Diagnostics, Other Diagnostics End-use (Hospitals, Clinics, Laboratories, and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
Technology | |
Whole Genome Sequencing | |
Whole Exome Sequencing | |
Targeted Sequencing & Resequencing Centrifuges |
Workflow | |
Pre-Sequencing | |
Sequencing | |
Data Analysis |
Application | ||||
| ||||
Companion Diagnostics | ||||
Other Diagnostics |
End-use | |
Hospitals | |
Clinics | |
Laboratories |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Clinical Oncology NGS Market Size Summary
The clinical oncology next-generation sequencing (NGS) market is poised for significant growth, driven by the increasing adoption of personalized medicine and advancements in cancer research. The market is experiencing a surge in demand due to the rising prevalence of cancer and the need for early diagnosis and treatment. The decreasing cost of genetic medicine and the development of precision therapies are further propelling market expansion. The COVID-19 pandemic has also played a role in accelerating the adoption of NGS technologies, as these tools have been utilized for diagnostic purposes and to understand viral mutations. The market is characterized by strategic collaborations and innovations, such as the development of automatic clinical oncology interpretation software platforms, which are expected to enhance the capabilities of genomic assays.
North America leads the clinical oncology NGS market, supported by regulatory efforts to increase cancer screening and a high concentration of key industry players. The region benefits from substantial investments in research and development, as well as strategic alliances that bolster market growth. Personalized medicine is becoming increasingly integral to clinical practice, influencing how diseases are diagnosed and treated. The market is highly competitive, with major players like Illumina, Inc., Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd. actively engaging in partnerships, product launches, and geographical expansions to strengthen their market presence. The introduction of advanced NGS-based panels and comprehensive genomic tests underscores the ongoing innovation and commitment to improving patient outcomes in precision oncology.
Global Clinical Oncology NGS Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Advancements in the Field of Personalized Medicine
-
1.2.2 Rising Burden of Cancer
-
1.2.3 Decrease in Costs for Genetic Sequencing
-
-
1.3 Market Restraints
-
1.3.1 Lack of computational efficiency for data management
-
1.3.2 Inadequate Reimbursement Policy
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 Technology
-
2.1.1 Whole Genome Sequencing
-
2.1.2 Whole Exome Sequencing
-
2.1.3 Targeted Sequencing & Resequencing Centrifuges
-
-
2.2 Workflow
-
2.2.1 Pre-Sequencing
-
2.2.2 Sequencing
-
2.2.3 Data Analysis
-
-
2.3 Application
-
2.3.1 Screening
-
2.3.1.1 Sporadic Cancer
-
2.3.1.2 Inherited Cancer
-
-
2.3.2 Companion Diagnostics
-
2.3.3 Other Diagnostics
-
-
2.4 End-use
-
2.4.1 Hospitals
-
2.4.2 Clinics
-
2.4.3 Laboratories
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle-East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle-East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Global Clinical Oncology NGS Market Size FAQs
What is the current Global Clinical Oncology NGS Market size?
The Global Clinical Oncology NGS Market is projected to register a CAGR of 16.90% during the forecast period (2024-2029)
Who are the key players in Global Clinical Oncology NGS Market?
Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies and Myriad Genetics are the major companies operating in the Global Clinical Oncology NGS Market.